Valuation: AbbVie Inc.

Market Cap 465B 411B 388B 352B 661B 44,645B 667B 4,660B 1,796B 22,798B 1,747B 1,709B 73,364B P/E 2026 *
33.3x
P/E 2027 * 24.9x
Enterprise Value 527B 465B 440B 399B 748B 50,555B 755B 5,277B 2,034B 25,816B 1,978B 1,935B 83,077B EV / Sales 2026 *
7.79x
EV / Sales 2027 * 7.05x
Free-Float
95.71%
Yield 2026 *
2.63%
Yield 2027 * 2.74%
1 day+31.58%
Current year-7.43%
Current year 176.4
Extreme 176.4
200.25
1 year 176.4
Extreme 176.4
200.25
3 years 164.86
Extreme 164.86
200.25
5 years 119.2
Extreme 119.2
200.25
10 years 119.2
Extreme 119.2
200.25
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Chief Tech/Sci/R&D Officer - 01/03/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 69 01/01/2013
Change 5-day change 1-year change 3-year change Capi.($)
+31.63%0.00% - - 465B
+0.15%+2.89%+55.21%+120.00% 1,056B
+0.01%-0.62%+44.27%+72.41% 645B
+0.12%-0.50%+13.92%+77.92% 465B
-1.43%-0.30%+75.91%+43.97% 368B
-0.13%-3.96%+34.21%+40.62% 335B
-0.22%+2.53%+20.44%+29.14% 275B
-0.93%-1.05%+10.00%+12.33% 255B
-0.28%+4.02%+49.68%+58.61% 229B
-0.87%-0.89%+35.15%+102.46% 188B
Average +2.74%+0.12%+37.64%+61.94% 423.98B
Weighted average by Cap. +3.11%+0.30%+41.64%+74.24%

Financials

2026 *2027 *
Net sales 67.6B 59.66B 56.44B 51.19B 95.97B 6,487B 96.92B 677B 261B 3,312B 254B 248B 10,659B 73.5B 64.86B 61.37B 55.65B 104B 7,052B 105B 736B 284B 3,601B 276B 270B 11,589B
Net income 14.07B 12.41B 11.75B 10.65B 19.97B 1,350B 20.17B 141B 54.3B 689B 52.82B 51.67B 2,218B 19.05B 16.81B 15.9B 14.42B 27.04B 1,828B 27.31B 191B 73.53B 933B 71.52B 69.96B 3,003B
Net Debt 61.59B 54.36B 51.43B 46.64B 87.44B 5,910B 88.31B 617B 238B 3,018B 231B 226B 9,712B 53.09B 46.85B 44.33B 40.2B 75.37B 5,094B 76.12B 532B 205B 2,601B 199B 195B 8,372B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
263.29USD
Average target price
278.86USD
Spread / Average Target
+5.91%

Quarterly revenue - Rate of surprise